Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 6/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL3650347 | 1.00 | TBXAS1 (0.36) | TBXAS1CYP2A6NAMPTHTR6MEN1 | |
| Fumaric Acid SCHEMBL3651792 | 0.90 | TBXAS1 (0.36) | TBXAS1CYP2A6NAMPTHTR6MEN1 | |
| Fumaric Acid SCHEMBL3651794 | 0.90 | TBXAS1 (0.36) | TBXAS1CYP2A6NAMPTHTR6MEN1 | |
| Fumaric Acid SCHEMBL4126583 | 0.87 | GAA (0.40) | TBXAS1CYP2A6NAMPTHTR6KMT2A | |
| Fumaric Acid SCHEMBL4126588 | 0.87 | GAA (0.40) | TBXAS1CYP2A6NAMPTHTR6KMT2A | |
| Fumaric Acid SCHEMBL3649699 | 0.87 | GPBAR1 (0.35) | TBXAS1CYP2A6NAMPTMEN1POLB | |
| Fumaric Acid SCHEMBL3649706 | 0.87 | GPBAR1 (0.35) | TBXAS1CYP2A6NAMPTMEN1POLB | |
| SCHEMBL3652974 | 0.81 | CYP2A6 (0.39) | CYP2A6NAMPTHTR6KMT2AL3MBTL1 | |
| SCHEMBL4126094 | 0.81 | NAMPT (0.35) | TBXAS1NAMPTPOLBALDH1A1 | |
| SCHEMBL4126083 | 0.81 | GPBAR1 (0.36) | TBXAS1NAMPTPOLBCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| EP-2190822-A2 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009041705-A9 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2009-08-13 | — | — | WO | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2009041705-A2 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | MEN1 1910/4885KMT2A 4776/4885TBXAS1 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.